The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Drug-Induced Interstitial Lung Disease

Heterogeneous group of pulmonary toxicities caused by chemotherapeutic agents (bleomycin, methotrexate, cyclophosphamide), targeted therapies (immune checkpoint inhibitors, EGFR-TKI), antiarrhythmics (amiodarone), antibiotics (nitrofurantoin), and biologics; presents with progressive dyspnea and cough, requiring drug withdrawal, corticosteroids, and supportive care.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Göğüs Hastalıkları department. Book Appointment →

What is Drug-Induced Interstitial Lung Disease?

Drug-induced interstitial lung disease (DI-ILD) encompasses pulmonary toxicities from over 350 medications causing inflammation, fibrosis, hypersensitivity, or non-cardiogenic pulmonary edema. Common offenders include chemotherapy (bleomycin causing dose-dependent fibrosis with potentiation by oxygen, methotrexate causing hypersensitivity pneumonitis, cyclophosphamide, busulfan), targeted therapies (EGFR-TKIs gefitinib/erlotinib/osimertinib, mTOR inhibitors, immune checkpoint inhibitors with ICI-pneumonitis), and immunomodulators.

Non-oncologic culprits include amiodarone (chronic interstitial pneumonitis with foamy macrophages, takes weeks-months), nitrofurantoin (acute hypersensitivity or chronic ILD), methotrexate (in rheumatoid arthritis), TNF inhibitors, leflunomide, and hundreds of others. Mechanisms include direct cytotoxicity, immunologic injury, oxidative stress, and idiosyncratic reactions. Recreational drugs (cocaine, opioids) and recently e-cigarette/vaping (EVALI) also cause acute lung injury patterns.

Diagnosis is one of exclusion: requires temporal relationship between drug exposure and symptoms, exclusion of other causes (infection, pulmonary edema, malignancy), suggestive HRCT pattern (organizing pneumonia, NSIP, hypersensitivity pneumonitis, eosinophilic pneumonia, diffuse alveolar damage), and improvement after drug withdrawal. BAL may show eosinophilia, lymphocytosis, or neutrophilia depending on pattern. Treatment: immediate drug cessation (most important), high-dose corticosteroids (1 mg/kg prednisone, IV methylprednisolone in severe cases), and supportive care; immune checkpoint inhibitor pneumonitis may require infliximab or mycophenolate for steroid-refractory cases.

Symptoms

Progressive dyspnea on exertion
Dry cough
Fatigue
Low-grade fever (especially hypersensitivity reactions)
Hypoxemia
Crackles on auscultation
Symptoms developing weeks-months after starting drug

Risk Factors

Chemotherapy or targeted therapy use
Long-term amiodarone use (cumulative dose-related)
Nitrofurantoin chronic prophylaxis
Pre-existing lung disease
Older age
Smoking history
Combination therapies (e.g., bleomycin + oxygen)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • New or worsening dyspnea on medication known to cause ILD
  • Persistent dry cough during chemotherapy
  • Sudden respiratory deterioration in patient on amiodarone
  • Hypoxemia or oxygen desaturation
  • Symptoms developing during immune checkpoint inhibitor therapy
  • Worsening lung function on routine monitoring
  • Fever and respiratory symptoms after new medication

Treatment Methods

01
Immediate discontinuation of suspected offending drug
02
High-dose corticosteroids (1 mg/kg prednisone) for moderate-severe disease
03
IV methylprednisolone for severe respiratory failure
04
Supplemental oxygen and supportive care
05
Mechanical ventilation if respiratory failure
06
Infliximab or mycophenolate for steroid-refractory ICI-pneumonitis
07
Avoid future exposure to causative drug class

Which Department to Visit?

You can visit our Göğüs Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Göğüs Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Asthma

Göğüs Hastalıkları

Asthma is characterized by wheezing, coughing and shortness of breath attacks; with proper treatment it can be kept under control.

COPD (Chronic Obstructive Pulmonary Disease)

Göğüs Hastalıkları

COPD is an irreversible lung disease characterized by shortness of breath and chronic cough; quitting smoking slows its progression.

Pneumonia

Göğüs Hastalıkları

Pneumonia presents with high fever, cough and shortness of breath; the vast majority recover with appropriate antibiotic treatment.

Tuberculosis (TB)

Göğüs Hastalıkları

Tuberculosis presents with weeks-to-months of cough, fever, and night sweats; early diagnosis and treatment lead to full recovery.

Pleural Effusion

Göğüs Hastalıkları

Pleural effusion is the accumulation of excess fluid in the pleural space, resulting from imbalances in fluid production and removal, and represents a manifestation of diverse cardiopulmonary, infectious, and malignant disorders.

Pneumothorax

Göğüs Hastalıkları

Pneumothorax is the presence of air in the pleural space resulting in partial or complete lung collapse, classified as spontaneous (primary/secondary), traumatic, or iatrogenic, with tension pneumothorax representing a life-threatening emergency.

Bronchitis (Acute and Chronic)

Göğüs Hastalıkları

Acute bronchitis is mostly viral and resolves spontaneously, while chronic bronchitis is a smoking-related component of COPD.

Bronchiectasis

Göğüs Hastalıkları

Bronchiectasis is a chronic respiratory disease characterized by permanent, abnormal dilation of bronchi with associated destruction of muscular and elastic components of airway walls, resulting in impaired mucociliary clearance and recurrent infection.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.